NCT02744287 - Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions

Metastatic Castration-resistant Prostate CancerMetastatic Prostate Cancer

Interventions

BIOLOGICAL

BPX-601

Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain

DRUG

Rimiducid

Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence

Trial Locations (13)

10032

Columbia University Medical Center, New York

14263

Roswell Park Cancer Institute, Buffalo

19107

Thomas Jefferson University, Philadelphia

27705

Duke University, Durham

30322

Emory Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

48201

Karmanos Cancer Institute, Detroit

60612

Rush University Medical Center, Chicago

60637

University of Chicago Medicine, Chicago

68198

University of Nebraska, Omaha

75246

Baylor Sammons Cancer Center, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

07601

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack